Company
Headquarters: Taichung, Taiwan
Employees: 19
CEO: Dr. Yung-Shun Wen Ph.D.
TW$11.60 Billion
TWD as of Jan. 1, 2024
US$378.0 Million
Company | Market Cap (USD) |
---|---|
Zoetis Inc. | $89.09 B |
MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
Takeda Pharmaceutical Company Limited | $47.71 B |
Haleon plc | $38.90 B |
PPD, Inc. | $16.58 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Alar Pharmaceuticals Inc. operates as a drug development company. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which primarily include opioid use disorder, chronic pain, and major depressive disorder. The company is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid addiction; and ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. The company was founded in 2016 and is based in Taichung, Taiwan.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Alar Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: TWSE: 6785 wb_incandescent